Report: Unsupported Drug Price Hikes Cost U.S. $815M in 2023

In 2023, drugmakers increased prices on five widely used drugs without new clinical evidence, costing U.S. patients and insurers an additional $815 million, according to a report by the Institute for Clinical and Economic Review. The largest spending increase was for Biktarvy, an HIV treatment by Gilead Sciences, which saw a 5.9% wholesale price hike, resulting in $359 million more in spending. Gilead claims some study data were overlooked or rejected, challenging the report's findings.